Disseminated intravascular coagulation complicating diagnosis of ROS1-mutant non-small cell lung cancer: A case report and literature review.
Benzamides
/ therapeutic use
Carcinoma, Non-Small-Cell Lung
/ diagnosis
Diagnosis, Differential
Disseminated Intravascular Coagulation
/ complications
Female
Humans
Indazoles
/ therapeutic use
Lung Neoplasms
/ diagnosis
Middle Aged
Mutation
Protein Kinase Inhibitors
/ therapeutic use
Protein-Tyrosine Kinases
/ genetics
Proto-Oncogene Proteins
/ genetics
ROS1 mutation
disseminated intravascular coagulation
non-small-cell lung cancer
oncogene addiction
paraneoplastic syndrome
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
12
06
2021
accepted:
21
06
2021
pubmed:
23
7
2021
medline:
29
1
2022
entrez:
22
7
2021
Statut:
ppublish
Résumé
Disseminated intravascular coagulation (DIC) is a rare paraneoplastic complication in advanced solid malignancies, with success of treatment and survival dependent on treatment of the underlying malignancy. Best estimates suggest an incidence of 1.6-6.8% in cancer, with risk factors being advanced disease, older age, and adenocarcinoma, especially of lung origin. Few cases, however, have reported on an association between DIC and oncogene-addicted lung cancers, especially those containing ROS proto-oncogene 1 (ROS1) mutations, however precedent exists to suggest increased prothrombotic rates in tumors harboring this mutation. We present a young woman with ROS1-mutant non-small-cell lung cancer who presented in DIC and subsequently developed complications of both hemorrhage and thrombosis. Following initiation of targeted treatment, rapid resolution of laboratory coagulation derangement was observed and clinical improvement quickly followed. This event underscores the need for rapid evaluation of lung molecular panels and the dramatic resolution of life-threatening illness that can occur with institution of appropriate therapy. This case contributes to growing evidence for a possible underlying link between oncogene addicted tumors and abnormalities of coagulation.
Identifiants
pubmed: 34291575
doi: 10.1111/1759-7714.14071
pmc: PMC8410535
doi:
Substances chimiques
Benzamides
0
Indazoles
0
Protein Kinase Inhibitors
0
Proto-Oncogene Proteins
0
Protein-Tyrosine Kinases
EC 2.7.10.1
ROS1 protein, human
EC 2.7.10.1
entrectinib
L5ORF0AN1I
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2400-2403Informations de copyright
© 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
Respir Med Case Rep. 2021 Mar 19;33:101393
pubmed: 33854939
Ther Clin Risk Manag. 2018 Aug 01;14:1361-1368
pubmed: 30122935
Lung Cancer. 2009 May;64(2):247-9
pubmed: 19070399
Clin Lung Cancer. 2018 Jan;19(1):e57-e61
pubmed: 28844392
BMC Res Notes. 2016 Mar 17;9:173
pubmed: 26987388
Lung Cancer. 2011 Mar;71(3):249-57
pubmed: 21216486
Thromb Res. 2018 Apr;164 Suppl 1:S77-S81
pubmed: 29703488
Lancet Oncol. 2020 Feb;21(2):261-270
pubmed: 31838015
J Int Med Res. 2018 Jan;46(1):533-537
pubmed: 28730909
Br J Haematol. 2021 Mar;192(5):803-818
pubmed: 33555051
Thromb Haemost. 2001 Nov;86(5):1327-30
pubmed: 11816725
Clin Lung Cancer. 2020 Jan;21(1):15-20
pubmed: 31607443
N Engl J Med. 1999 Aug 19;341(8):586-92
pubmed: 10451465
Nat Rev Clin Oncol. 2021 Jan;18(1):35-55
pubmed: 32760015
Thromb Res. 2018 Mar;163:51-53
pubmed: 29353684
J Thorac Oncol. 2013 Nov;8(11):e96-8
pubmed: 24128725
Thorax. 2006 Nov;61(11):1009-10
pubmed: 17071837
Cancers (Basel). 2020 Nov 06;12(11):
pubmed: 33172113
Thorac Cancer. 2021 Sep;12(17):2400-2403
pubmed: 34291575
Thromb Haemost. 2001 Sep;86(3):828-33
pubmed: 11583315